The field of nuclear medicine has seen tremendous advancements, particularly in the development of radiopharmaceuticals for targeted cancer diagnosis and therapy. At the heart of many of these groundbreaking agents is DOTA (1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid, CAS 60239-18-1). This macrocyclic chelator plays a crucial role by securely binding medically relevant radioisotopes, enabling their precise delivery to tumor sites.

DOTA's exceptional ability to chelate a wide range of medically important metal radionuclides, such as Yttrium-90 (90Y), Lutetium-177 (177Lu), Gallium-68 (68Ga), and Copper-64 (64Cu), makes it an indispensable building block in radiopharmaceutical chemistry. The stability of DOTA complexes with these isotopes is paramount; it ensures that the radioactive payload remains attached to the targeting molecule throughout its journey in the body and upon reaching its target, minimizing off-target radiation exposure and maximizing therapeutic efficacy. This robust chelation is critical for both diagnostic imaging (like PET scans) and targeted radionuclide therapy.

NINGBO INNO PHARMCHEM CO.,LTD. is a dedicated manufacturer and supplier of high-quality DOTA, a vital pharmaceutical intermediate for the radiopharmaceutical industry. We understand the critical need for purity and consistency in this sector. Our DOTA, with a guaranteed purity of 98%min, serves as a reliable foundation for developing innovative radiotherapeutics and diagnostics. We offer competitive pricing and a stable supply chain, making it easier for researchers and manufacturers to purchase DOTA and advance their critical projects. Partner with us to secure your supply of this essential chelator and contribute to the fight against cancer.

The chemical properties of DOTA (C16H28N4O8, MW 404.42) are well-suited for conjugation to antibodies, peptides, and other targeting vectors. This allows for highly specific delivery, targeting disease sites with unprecedented precision. As your trusted supplier in China, NINGBO INNO PHARMCHEM is committed to supporting the global radiopharmaceutical market with high-grade DOTA. Contact us today to discuss your requirements and how we can facilitate your R&D and production needs.